Search

Displaying results 3271 - 3280 of 10000 in total
  1. Drug

    Fluoride ion

    go.drugbank.com/drugs/DB11257
    ApprovedInvestigational

    Fluoride ions are found in various minerals but are only present in trace amounts in water.

    Mixtures: ZYMAFLUOR D 1000, ZYMAFLUOR D 500
  2. Drug

    Birabresib

    go.drugbank.com/drugs/DB15189
    Investigational

    Birabresib is under investigation in clinical trial NCT02698176 (A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006)).

  3. Drug

    Meningococcal polysaccharide vaccine group W-135

    go.drugbank.com/drugs/DB13887
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.

    Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET
  4. Drug

    Meningococcal polysaccharide vaccine group Y

    go.drugbank.com/drugs/DB13888
    ApprovedInvestigational

    It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup Y.

    Mixtures: MENCEVAX ACWY 0,5 ML SC ENJEKSİYON İÇİN LİYOFİLİZE TOZ İÇEREN ÇOK DOZLU FLAKON, 50 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET
  5. Drug

    Rolapitant

    go.drugbank.com/drugs/DB09291
    ApprovedInvestigational

    late-phase CINV during the first 120 hours post-chemotherapy. … Unlike other available NK-1 receptor antagonists, rolapitant is not an inhibitor of Cytochrome P450 enzyme CYP3A4 and has a long elimination half-life, allowing a single dose to prevent both acute and

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors
  6. Drug

    Relmapirazin

    go.drugbank.com/drugs/DB19130
    Investigational

    Relmapirazin is under investigation in clinical trial NCT05425719 (Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the Medibeacon Transdermal GFR Measurement System in Evaluation of Kidney Function

  7. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]

  8. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584]. … CBDV has also been shown to inhibit the activity of diacylglycerol (DAG) lipase-α, the primary enzyme responsible for the synthesis of the endocannabinoid, 2-arachidonoylglycerol (2-AG) [A33296, A33347

    Synonyms: 2-[(1R,6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-5-propylbenzene-1,3-diol
  9. Drug

    Andusomeran

    go.drugbank.com/drugs/DB18227
    ApprovedInvestigational

    [L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.

  10. Drug

    Rozibafusp Alfa

    go.drugbank.com/drugs/DB19233
    Investigational

    Rozibafusp Alfa is under investigation in clinical trial NCT04058028 (Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)).

    Synonyms: IMMUNOGLOBULIN G2-KAPPA, ANTI-(HUMAN INDUCIBLE COSTIMULATOR (ICOS) LIGAND PROTEIN) HUMAN MONOCLONAL ANTIBODY, FUSED WITH TWO COPIES OF A TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13B (TNFSF13B, B-CELL